Skip to content

A RCT on the patients with hepatocellular carcinoma receiving chemotherapy of arsenic trioxide for preventing tumor recurrence after hepatectomy

A RCT on the patients with hepatocellular carcinoma receiving chemotherapy of arsenic trioxide for preventing tumor recurrence after hepatectomy

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-13003244
Enrollment
Unknown
Registered
2013-05-09
Start date
2013-06-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hepatocellular carcinoma

Interventions

Group A:Patients accept chemotherapy of arsenic trioxide after liver resection
Group B:Patients accept liver resection

Sponsors

Eastern Hepatobiliary Surgical Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. 18 to 70 years old male or non-pregnant female hepatocellular carcinoma patients with curative resection; 2. Pathologically proved primary liver cancer, R0 resection, pathological resection margin (-), without extrahepatic metastasis or adjacent organ involvement before surgery; 3. liver function is Child-Pugh A or B; 4. No apparent abnormality of the heart, lung, and kidney; 5. No HCV, HIV and syphilis infection; 6. Patients should sign the informed consent of this study.

Exclusion criteria

Exclusion criteria: 1. If preoperative liver function is Child C, it cannot tolerate Surgery; 2. With evidence of extrahepatic metastasis; 3. With evidence of unstable angina pectoris, symptomatic congestive heart failure, severe arrhythmia, acute myocardial infarction within the last six months, prolonged QT interval (>450ms); 4. Malignant or metastatic tumor in other sites in last 5 years; 5. Patients can not be followed-up regularly; 6. Patients participating in other trials.

Design outcomes

Primary

MeasureTime frame
Overall survival;Disease-free survival;radiographic parameters;Liver function;

Contacts

Public ContactCheng Shuqun
chengshuqun@yahoo.com.cn+86 13901746139

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026